The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global poultry vaccines market reached a value of US$ 1.67 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.47 Billion by 2027, exhibiting at a CAGR of 6.59% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Poultry disease is an infectious animal disease affecting poultry species, such as duck, chicken, turkey, and goose. It causes facial edema, diarrhea, twisting of neck and paralysis of wings and legs, cyanosis of comb, reduction in egg production, and sudden death. As a result, poultry animals undergo vaccination to stimulate their immune mechanism and produce antibodies, which inactivates pathogens. The vaccination also assists in preserving the productive health of these animals by acting as a protective measure against the outbreak of contagious diseases. At present, it can be administered via injections, feed, eye-drop, and drinking water.
There is currently an increase in the prevalence of zoonotic diseases like avian influenza or bird flu that spreads among animals and infects humans. This, along with the escalating demand for animal health diagnostics, represents one of the key factors strengthening the growth of the market. Apart from this, the increasing consumption of animal-derived products and rising concerns about food safety around the world are contributing to market growth. Furthermore, leading market players are considerably investing in research and development (R&D) activities to introduce poultry vaccines that help protect against avian diseases, such as infectious bronchitis, infectious bursal diseases, and virulent Newcastle disease (VND). They are also utilizing advanced technologies to manufacture effective vaccines, which is creating a favorable market outlook. Besides this, the growing awareness among veterinary practitioners about animal vaccination is positively influencing the market. Other major factors, including a significant rise in the spending on animal health worldwide, an increase in the poultry population, and the introduction of live, non-replicating recombinant antigens, nucleic acid-mediated, and live-gene detected vaccines, are projected to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global poultry vaccines market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on disease, product, dosage form, application and end user.
Breakup by Disease:
Breakup by Product:
Breakup by Dosage Form:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AniCon Labor GmbH (SAN Group), Biovac Ltd., Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco, Hester Biosciences Limited, Merck & Co. Inc., Phibro Animal Health Corporation, Venkys India and Zoetis Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Disease, Product, Dosage Form, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AniCon Labor GmbH (SAN Group), Biovac Ltd., Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco, Hester Biosciences Limited, Merck & Co. Inc., Phibro Animal Health Corporation, Venkys India and Zoetis Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at